BlackRock, Inc. 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BlackRock Inc. BLK |
17,483,490 8.400% |
-3,558,982 (-16.91%) |
Filing |
| 2024-09-10 12:09 pm Purchase |
2024-08-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BlackRock Inc. BLK |
21,042,472 10.200% |
2,361,102 (+12.64%) |
Filing |
| 2024-01-24 5:23 pm Purchase |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BlackRock Inc. BLK |
18,681,370 9.100% |
3,762,415 (+25.22%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BlackRock Inc. BLK |
14,918,955 8.000% |
131,560 (+0.89%) |
Filing |
| 2022-02-01 5:08 pm Sale |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BlackRock Inc. BLK |
14,787,395 8.200% |
-1,472,350 (-9.06%) |
Filing |
| 2021-01-28 5:56 pm Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BlackRock Inc. BLK |
16,259,745 9.200% |
4,109,534 (+33.82%) |
Filing |